Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 13.066
Filter
1.
ABCS health sci ; 45: [1-7], 02 jun 2020. tab
Article in English | LILACS (Americas) | ID: biblio-1097559

ABSTRACT

INTRODUCTION: Long-term disabilities are frequently related to postoperative complications on breast cancer patients. OBJECTIVE: To assess the effect of breast cancer surgery on pulmonary function and respiratory muscle strength over the course of 60 days after the surgery. METHODS: Prospective study with 32 women. Pulmonary function was evaluated using spirometry and respiratory muscle strength was evaluated using manovacuometry. The evaluations were performed in preoperative period, between 12 to 48h after surgery, 30 and 60 days after the surgery. RESULTS: Vital capacity (VC) and inspiratory capacity (IC) were diminished 48h after surgery (VC: 2.18±0.63; IC: 1.71±0.49; p<0.01 vs baseline), returned to the baseline parameters after 30 days (VC: 2.76±0.60; CI: 2.16±0.57; p<0.01 vs PO48h) and were maintained after 60 days of the surgery (VC: 2.64±0.60; CI: 2.11±0.62; p<0.01 vs PO48h). No difference was observed in tidal volume over the evaluations, except when comparing 60 days to the 48h after surgery values (0.84±0.37 vs 0.64±0.19, respectively; p=0.028). Respiratory muscle strength was reduced 48h after surgery (MIP: -33.89±12.9 cmH2O; MEP: 39.72±21.0 cmH2O; p<0.01 vs basal) and returned to baseline values after 30 (MIP: -50.1±21.2 cmH2O; MEP: 59.86±24.7 cmH2O; p<0.01 vs PO48h) and 60 days of the surgery (MIP: -50.78±19.2 cmH2O; MEP: 61.67±23.4 cmH2O; p<0.01vs PO48h). CONCLUSION: Breast cancer surgery does not impact pulmonary function and respiratory muscle strength 30 days after the surgery.


INTRODUÇÃO: Mulheres com câncer de mama podem apresentar complicações a longo-prazo relacionadas ao procedimento cirúrgico. OBJETIVO: Avaliar a função pulmonar e a força muscular respiratória em mulheres submetidas a tratamento cirúrgico para câncer de mama ao longo de 60 dias. MÉTODOS: Estudo longitudinal com 32 mulheres. A função pulmonar e a força muscular respiratória foram avaliadas utilizando espirometria e manovacuometria, respectivamente, no pré-operatório, de 12 a 48h no período pós-operatório, 30 dias e 60 dias após a cirurgia. RESULTADOS: A capacidade vital (CV) e a capacidade inspiratória (CI) apresentaram redução significante no pós-operatório de até 48h (CV: 2,18±0,63; CI: 1,71±0,49; p<0,01 vs basal), com retorno aos parâmetros basais em 30 dias após a cirurgia (CV: 2,76±0,60; CI: 2,16±0,57; p<0,01 vs PO48h) e manutenção destes no pós-operatório de 60 dias (CV: 2,64±0,60; CI: 2,11±0,62; p< 0,01 vs PO48h). Não foi observada diferença estatisticamente significante entre os valores de volume corrente nos quatro períodos avaliados, exceto quando comparado o período pós-operatório de 60 dias com o pós-operatório de até 48h (0,84±0,37 vs 0,64±0,19, respectivamente; p=0,028). Todos os valores de força muscular respiratória apresentaram-se significantemente reduzidos no pós-operatório de até 48h (PImax: -33,89±12,9 cmH2O; PEmax: 39,72±21,0 cmH2O; p<0,01 vs basal), com retorno aos valores basais em 30 (PImax: -50,1±21,2 cmH2O; PEmax: 59,86±24,7 cmH2O; p<0,01 vs PO48h) e 60 dias (PImax -50,78±19,2 cmH2O; PEmax 61,67±23.4 cmH2O; p<0,01 vs PO48h). CONCLUSÃO: A cirurgia para tratamento do câncer de mama não impacta na função pulmonar e força muscular respiratória 30 dias após a cirurgia.


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Spirometry , Respiratory Muscles , Breast Neoplasms/surgery
3.
Rev. argent. mastología ; 39(142): 5-11, jun. 2020.
Article in Spanish | LILACS (Americas) | ID: biblio-1104075

ABSTRACT

El 12 de diciembre de 2019 el mundo era rutinariamente normal y, muy escuetamente, las noticias mencionaban algunos casos de una rara neumonía viral observados en Wuhan, Provincia de Hubei, China. Entre el 30 de diciembre y el 3 de enero de 2020, todo drásticamente cambió. Se denunció, primero en un chat, una rara epidemia y, posteriormente, fue desmentida en un documento por quien la denunció, el oftalmólogo chino Li Weliang, bajo coacción del gobierno de su país "acusándolo de difundir rumores falsos". Dos días después, la Organización Mundial de la Salud (oms) alertó sobre un brote de neumonía de etiología desconocida en Wuhan; y recién el 7 de enero las autoridades chinas comunican que han identificado un nuevo virus causante de la nueva enfermedad: el 2019-nCoV


Subject(s)
Pneumonia , Pneumonia, Viral , Therapeutics , Breast Neoplasms , Coronavirus Infections , Epidemics
4.
Rev. argent. mastología ; 39(142): 12-40, jun. 2020. ilus
Article in Spanish | LILACS (Americas) | ID: biblio-1104080

ABSTRACT

Introducción El Carcinoma Lobulillar Invasor (cli) es el tipo histológico especial más común del cáncer de mama. Presenta características histopatológicas asociadas a buen pronóstico, pero algunos estudios sugieren que los resultados a largo plazo pueden ser peores que los del Carcinoma Ductal Invasor (cdi). Objetivo Los objetivos principales del estudio fueron evaluar las características clínico-patológicas del cli y establecer el valor pronóstico. Material y método Se seleccionaron 244 pacientes con cli y se utilizó como grupo control a 524 pacientes con cdi, comparándolas con relación 2 a 1. Resultados No se observaron diferencias en edad, estado menopáusico, motivo de consulta e invasión linfovascular. Fueron más frecuentemente multifocales, multicéntricos, de mayor tamaño, bajo grado histológico y her2 negativo. La cirugía conservadora se realizó con menos frecuencia. No hubo diferencias significativas en recaída a distancia, cáncer de mama contralateral, sobrevida libre de enfermedad y global. Conclusiones Las pacientes con cli no tuvieron mejores resultados a pesar de un fenotipo biológico más favorable. La histología ductal o lobulillar no debería ser un factor en el manejo de la patología, y no debería considerarse un factor pronóstico o predictivo determinante al momento del diagnóstico


Introduction Invasive Lobular Carcinoma (ilc) is the second most common histologic type of breast cancer. Typically, displays features associated with a good prognosis, but some studies suggest that outcomes of ilc may be worse than for Invasive Ductal Carcinoma (idc). Objective The main purpose of this study was to evaluate the clinical-pathological characteristics of Lobular Breast Carcinoma and establish his prognostic value. Materials and method We selected a group of 244 patients with ilc and compared with 524 patients whit idc in relation 2:1. Results There were no differences in age, menopausal status, symptoms at time of diagnosis, and lymph vascular invasion. ilc were larger, low histological grade and her2 negative, more often mulfifocal and multicentric. Breast-preservation therapy was less frequent for Invasive Lobular Carcinoma. Distant relapse, contralateral cancer, overall survival, disease-free survival, did not differ between idc and ilc. Conclusions Women with ilc do not have better clinical outcomes than patients with idc, despite the fact that the biologic phenotype of ilc is quite favorable. The ductal or lobular histology should not be a factor in the therapeutic decision-making process, and should not be considered an important prognostic or predictive factor at diagnosis


Subject(s)
Breast Neoplasms , Carcinoma, Lobular , Carcinoma, Ductal
5.
Rev. argent. mastología ; 39(142): 52-90, jun. 2020. graf
Article in Spanish | LILACS (Americas) | ID: biblio-1104088

ABSTRACT

El cáncer de mama Estadio IV se define como la diseminación de células tumorales más allá de la mama, la pared torácica y los ganglios linfáticos regionales. Globalmente, 5-10% de las mujeres tienen metástasis al momento del diagnóstico y hasta un 30% de aquellas con estadios tempranos al inicio desarrollará metástasis en algún momento. Se estima una mediana de sobrevida global en cáncer de mama metastásico de 3 años, con un intervalo que va desde pocos meses hasta muchos años, y una sobrevida a 5 años que ronda el 25%. Continúa siendo una enfermedad tratable pero no curable. Los objetivos terapéuticos en enfermedad metastásica principalmente son: prolongación de la sobrevida global y libre de enfermedad, disminución de síntomas y complicaciones asociadas al cáncer y mejoras en la calidad de vida de las pacientes. En la actualidad, estas metas son alcanzadas principalmente con la utilización de terapias sistémicas como la quimioterapia, la hormonoterapia o el uso de agentes biológicos. En algunas circunstancias, el tratamiento locorregional también contribuye a lograr estos objetivos. La elección del tratamiento sistémico está principalmente determinada por la biología tumoral, ya que esto permite el empleo de terapias dirigidas. En los tumores Luminales, deberá emplearse hormonoterapia, sola o en asociación con otros esquemas. En tumores her2+, se indicará, de ser posible, como primera línea de tratamiento doble bloqueo anti-her más quimioterapia. El subgrupo de peor pronóstico está representado por los tumores Triple Negativos, para los cuales no existen blancos terapéuticos dirigidos. En este caso, se utilizará quimioterapia. Se deberá usar terapia de mantenimiento luego de lograr el control de la enfermedad en tumores Luminales y her2+. El rol del tratamiento locorregional en cáncer de mama metastásico continúa siendo un tema de debate. Actualmente, algunos estudios sugieren que podrían obtenerse algunos beneficios, aunque aún hacen falta más datos para sostener su indicación. Deberá garantizarse un abordaje multidisciplinario y un seguimiento cercano de estas pacientes, con el fin de valorar la respuesta al tratamiento, la aparición de toxicidad inaceptable y las condiciones de calidad de vida


Stage IV breast cancer is defined as the spread of tumor cells beyond the breast, chest wall, and regional lymph nodes. Globally, 5-10% of women have metastases at diagnosis, and up to 30% of those with early stages of onset will develop metastases at some point. A median overall survival in metastatic breast cancer of 3 years is estimated, with an interval ranging from a few months to many years, and a 5-year survival of around 25%. It remains a treatable but not curable disease. The therapeutic goals in metastatic disease are mainly: prolongation of global and disease-free survival, decrease in symptoms and complications associated with cancer, and improvements in the quality of life of patients. At present, these goals are mainly achieved with the use of systemic therapies such as chemotherapy, hormonal therapy or the use of biological agents. In some circumstances locoregional treatment also contributes to achieving these goals. The choice of systemic treatment is mainly determined by tumor biology, since this allows the use of targeted therapies. In Luminal tumors, hormone therapy should be used, alone or in association with other schemes. In her2+ tumors, double blocking anti-her plus chemotherapy will be indicated if possible as the first line of treatment. The worst prognosis subgroup is represented by Triple Negative tumors for which there are no targeted therapeutic targets. In this case chemotherapy will be used. Maintenance therapy should be used after achieving control of the disease in Luminal tumors and her2+. The role of locoregional treatment in metastatic breast cancer continues to be a matter of debate. Currently some studies suggest that some benefits could be obtained although more data are still needed to support its indication. A multidisciplinary approach and close monitoring of these patients should be guaranteed in order to assess the response to treatment, the appearance of unacceptable toxicity and quality of life conditions


Subject(s)
Phenobarbital , Breast Neoplasms , Drug Therapy
7.
Univ. salud ; 22(1): 41-51, ene.-abr. 2020. tab
Article in Spanish | LILACS (Americas), COLNAL | ID: biblio-1094578

ABSTRACT

Introducción: La prevalencia del cáncer es un problema que vas más allá de la preocupación médica, por cuanto involucra aspectos subjetivos y sociales en la vida de quienes lo padecen o están en riesgo. Por esto, es de gran importancia detectarlo tempranamente, especialmente entre mujeres debido a su exposición a los factores de riesgo de cáncer de mama y cérvix. Objetivo: Analizar la abstención femenina en Chile a la Mamografía y Papanicolaou. Materiales y métodos: Se realizó un análisis multivariado de regresión logística binomial, de los datos disponibles en el Módulo de Salud de la Encuesta de Caracterización Socioeconómica Nacional (CASEN) en su edición del año 2015. Resultados: Se expone una generalizada abstención a la acción preventiva entre mujeres, aun cuando la prevalencia de ambos tipos de cáncer es alta. Los motivos personales aparecen como los más comunes para omitir Mamografía y/o Papanicolaou, especialmente la subvaloración de su importancia. Los factores que aumentan la probabilidad de abstención son la baja escolaridad, la ausencia de afiliación médica y la presencia de pareja. Conclusiones: Se plantea la necesidad de aumentar igualmente la cobertura del servicio preventivo, focalizar los recursos hacia la población vulnerable y mejorar las estrategias de incentivo hacia estos exámenes.


Introduction: The prevalence of cancer is a problem that goes beyond medical concern since it involves subjective and social aspects that affect the lives of those who either suffer from cancer or are at risk for it. Therefore, it is important to detect it early, especially among women due to their exposure to risk factors for breast and cervical cancer. Objective: To analyze women's abstention from mammography and Papanicolaou screening in Chile. Materials and methods: A multivariate binomial logistic regression analysis was conducted with available data from the Health Module of the National Socioeconomic Characterization Survey (NSCS) from 2015. Results: Even though there is a high prevalence of both types of cancer, there is a generalized female abstention from preventive actions. Personal reasons are the most common justifications given for avoidance of mammography and/or Papanicolaou test, especially undervaluing their importance. Factors that increase the probability of abstention include low education level, lack of medical affiliation, and presence of a partner. Conclusions: It is important to increase the coverage of preventive services, focus resources towards vulnerable populations, and create incentive strategies for women to take these exams.


Subject(s)
Female , Breast Neoplasms , Papanicolaou Test , Mammography , Uterine Cervical Neoplasms , Disease Prevention
8.
Int. j. morphol ; 38(2): 448-457, abr. 2020. tab, graf
Article in English | LILACS (Americas) | ID: biblio-1056461

ABSTRACT

Inconsistent data are available on the relation between breast cancer, adiposity, body size and somatotype. The aim of our study was to compare anthropometric characteristics, body composition and somatotype between breast cancer patients and healthy controls. Study group consisted of 106 breast cancer patients while control group consisted of 100 healthy women who underwent 29 anthropometric measurements. Women with breast cancer expressed more male anthropometric features like higher stature (160.75±6.91 vs. 158.17±4.89 cm, p=0.020), shorter trunk (sitting height in premenopausal: 84.94±5.07 vs. 88.50±3.84 cm, p=0.001 and postmenopausal women: 81.96±6.08 vs. 85.19±3.36 cm, p=0.001), narrower hips (29.20±3.78 vs. 32.24±1.78 cm, p=0.000), higher biepicondylar diameter of humerus (premenopausal: 6.64±0.71 vs. 6.31±0.42 cm, p=0.012; postmenopausal: 6.95±0.63 vs. 6.54±0.49 cm, p=0.000), larger upper- and forearm as well as upper thigh circumferences followed by lower biceps and higher thigh skinfold thicknesses. They also had significantly lower endomorphy (premenopausal: 5.84±1.78 vs. 6.55±0.96, p=0.027; postmenopausal: 6.89±1.52 vs. 7.37±0.86, p=0.035) and significantly higher ectomorphy (premenopausal: 2.05±1.30 vs. 1.41±0.99, p=0.018; postmenopausal: 1.06±0.90 vs. 0.68±0.56, p=0.007), as well as higher mesomorphy only in postmenopausal women (6.10±2.04 vs. 5.37±1.34, p=0.022). Most represented somatotype among breast cancer patients was endomorph-mesomorph while the most healthy controls were mesomorphic endomorph. Android body type increases the risk of development of breast cancer. Indicators of skeletal dimensions, muscle volume and peripheral adiposity had better predictive value over markers of central and overall adiposity.


La información en la literatura es variable sobre la relación entre el cáncer de mama, la adiposidad, el tamaño corporal y somatotipo de las mujeres. El objetivo de este estudio fue comparar las características antropométricas, la composición corporal y el somatotipo entre pacientes con cáncer de mama y controles sanos. El grupo de estudio consistió en 106 pacientes con cáncer de mama y el grupo de control de 100 mujeres sanas que se sometieron a 29 mediciones antropométricas. Las mujeres con cáncer de mama tenían mayor cantidad características antropométricas masculinas, tal como una estatura más alta (160.75±6.91 vs. 158.17±4.89 cm, p = 0.020), tronco más corto (altura sentada en premenopáusica: 84.94±5.07 vs. 88.50±3.84 cm, p = 0.001 y mujeres posmenopáusicas: 81.96±6.08 vs. 85.19±3.36 cm, p = 0.001), caderas más estrechas (29.20±3.78 vs. 32.24±1.78 cm, p = 0.000), mayor diámetro biepicondilar del húmero (premenopáusico: 6.64±0.71 vs. 6.31 ±0.42 cm, p = 0.012; posmenopáusica: 6.95±0.63 vs. 6.54±0.49 cm, p = 0.000), mayor circunferencia del antebrazo y la parte superior del muslo, bíceps inferiores y mayor grosor del pliegue de la piel del muslo. Además se observó una endomorfia significativamente menor (premenopáusica: 5.84±1.78 vs. 6.55±0.96, p = 0.027; posmenopáusica: 6.89±1.52 vs. 7.37±0.86, p = 0.035) y una ectomorfia significativamente más alta (premenopáusica: 2.05±1.30 vs. 1.41 .990.99, p = 0.018; posmenopáusica: 1.06±0.90 vs. 0.68±0.56, p = 0.007), así como una mayor mesomorfia solo en mujeres posmenopáusicas (6.10±2.04 vs. 5.37±1.34, p = 0.022). El somatotipo más representado entre las pacientes con cáncer de mama fue el endomorfomesomorfo, mientras que los controles más sanos fueron el mesomórfico endomorfo. Las características del cuerpo tipo androide aumenta el riesgo de desarrollar cáncer de mama. Los indicadores de dimensiones esqueléticas, volumen muscular y adiposidad periférica tuvieron un mejor valor predictivo sobre los marcadores de adiposidad central y general.


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Somatotypes , Breast Neoplasms/pathology , Anthropometry , Body Composition , Case-Control Studies
9.
Rev. argent. mastología ; 39(141): 5-14, mar. 2020.
Article in Spanish | LILACS (Americas) | ID: biblio-1104359

ABSTRACT

En el año 2018, James Allison y Tasuku Honjo fueron galardonados con el Premio Nobel de Medicina por haber descubierto el rol fisiológico de 2 proteínas, CTLA-4 y PD-1 respectivamente. Estas proteínas son receptores de membrana expresados en las células del sistema inmune y tejidos periféricos involucrados en el mantenimiento de la auto-tolerancia y modelación de la respuesta inmune para prevenir reacciones de autoinmunidad. La activación de estos receptores en los Linfocitos T citotóxicos CD8+(lt CD8+) por parte de las células tumorales determina la inhibición de la proliferación de los lt CD8+, permitiendo que el tumor evada la respuesta inmune


Subject(s)
Breast Neoplasms , Immune System , Immunotherapy
10.
Rev. argent. mastología ; 39(141): 34-46, mar. 2020. graf
Article in Spanish | LILACS (Americas) | ID: biblio-1104369

ABSTRACT

Objetivo El objetivo del presente trabajo es evaluar el valor adicional del spect/ct sobre el Centellograma de Cuerpo Entero (cce) y la spect en pacientes con cáncer de mama con mínimo dos estudios: tiempo inicial (i) y evolución (e). Material y método Se evaluaron retrospectivamente 208 lesiones en 186 pacientes. Se realizaron imágenes: cce, spect y spect/ct del esqueleto axial con 99mTcmdp y equipo híbrido Infinia Hawkeye 4 GE. Las lesiones se caracterizaron del siguiente modo: benigna (b); maligna (m); y equívocas: probablemente benigna (pb) y probablemente maligna (pm). Resultados spect/cti clasificó 197/208 lesiones (94,7%), specti 155/208 (74,5%) y ccei 130/208 (51%). Los tres métodos coincidieron inicialmente en 138 lesiones: 106 b (77%), 23 m (17%) y 9 equívocas (6%), y en la evolución en 155: 110 b (71%), 44 m (28%), 1 equívoca (1%). La sensibilidad, especificidad y exactitud inicial para diagnóstico de metástasis (incluyendo como malignas las lesiones probablemente malignas) fueron 92/70/51% (ccei), 100/78/75% (specti) y 100/97/95% (spect/cti). Diferencias de a pares: ccei vs specti y spect/cti para sensibilidad (p<0,05) y specti y ccei vs spect/cti especificidad y exactitud (p<0,001). Conclusiones El aporte de spect/ct incrementó la precisión y certeza diagnóstica para diferenciar las lesiones benignas, malignas y equívocas. Su utilización debería ser rutinaria en la detección de metástasis óseas en pacientes con carcinoma de mama


Objective To assess the additional value of spect/ct on whole-body scintigraphy (wbs) and spect in patients with breast cancer, with a minimum of two tests: start time (i) and assessment (e). Materials and method Retrospective assessment of 208 lesions in 186 patients. Images were taken by wbs, spect and spect/ct of the axial skeleton with 99mTc- mdp and hybrid equipment Infinia Hawkeye 4 GE. Characterization of the lesions: benign (b), malignant (m) and equivocal: likely to be benign or malignant. Results By using spect/cti, 197/208 lesions (94.7%), specti 155/208 (74.5%) and wbsi 130/208 (51%) were classified. The three methods initially coincided on 138 lesions: 106 b (77%), 23 m (17%) and 9 equivocal (6%); and on assessment on 155: 110 b (71%), 44 m (28%), 1 equivocal (1%). The initial sensitivity, specificity and accuracy for the diagnosis of metastases (including as malignant those lesions which were likely to be so) were as follows: 92/70/51% (wbsi), 100/78/75% (specti) and 100/97/95% (spect/cti). Differences by pairs: wbsi vs specti and spect/cti for sensitivity (p<0,05) and specti and wbsi vs spect/cti for specificity and accuracy (p<0,001). On assessment 99%. Conclusions The contribution of spect/ct has increased diagnostic accuracy and certainty to differentiate benign, malignant and equivocal lesions. It should be used routinely for the detection of bone metastases in patients with breast cancer


Subject(s)
Breast Neoplasms , Tomography, Emission-Computed, Single-Photon , Neoplasm Metastasis
11.
J. health med. sci. (Print) ; 6(1): 21-27, ene.-mar. 2020. tab, ilus
Article in Spanish | LILACS (Americas) | ID: biblio-1096529

ABSTRACT

El cáncer de mama es una de las patologías más frecuentes a nivel mundial y en el Ecuador ocupa un sitio importante dentro de la mortalidad; en pacientes con tumores de estadios avanzados la quimioterapia neodyuvante es el procedimiento indicado para lograr una reducción tumoral satisfactoria. El objetivo fue determinar la respuesta clínica y patológica en pacientes con cáncer de mama tratadas con quimioterapia neoadyuvante según cada subtipo molecular, atendidos en el hospital "Teodoro Maldonado Carbo" en el período 2015 a 2017. Se hizo uso de un diseño no experimental, transversal de tipo correlacional. Pacientes con cáncer de mama que recibieron neoadyuvancia, en su mayoría con quimioterapia basada en antraciclinas y taxanos. Se clasificó a las pacientes por sus subtipos moleculares, los mismos se obtuvieron en base a las características inmunohistoquímicas de los reportes de patología que constan en el sistema AS-400. Se comprobó la respuesta clínica al tratamiento usando los Criterios RECIST 1.1. Como resultado los 171 pacientes fueron analizados. La edad promedio de las pacientes fue 55 13 años de edad; el 25% fueron luminal B (HER+), 24% luminal B (HER-), 22% triple negativo, 18% HER2+ y 12% luminal A; el 52% de las pacientes tuvieron estadio III de la enfermedad; el 75% (129) de las pacientes fue realizada una mastectomía radical modificada. Se pudo concluir que la respuesta patológica completa en pacientes con tratamiento neoadyuvante se relaciona con los subtipos moleculares y esto es estadísticamente significativo. Además, se evidenció las mayores tasas de respuesta patológica completa en los grupos moleculares de HER2+ y triple negativo.


Breast cancer is one of the most frequent pathologies worldwide and in Ecuador it occupies an important place in mortality. In patients with advanced stage tumors, the neo-adjuvant chemotherapy is the indicated procedure to achieve a satisfactory tumor reduction. The aim was to determine the clinical and pathological response in patients with breast cancer treated with neoadjuvant chemotherapy according to each molecular subtype, treated at the "Teodoro Maldonado Carbo" hospital in the period 2015 to 2017. We used a non-experimental, crosssectional type design. Patients with breast cancer who received neoadjuvant, mostly with chemotherapy based on anthracyclines and taxanes. The patients were classified by their molecular subtypes, they were obtained based on the immunohistochemical characteristics of the pathology reports that appear in the AS-400 system. The clinical response to treatment was checked using the RECIST 1.1 Criteria. As a result, a sum of 171 patients were analyzed. The average age of the patients was 55 + 13 years old; 25% were luminal B (Her +), 24% luminal B (Her-), 22% triple negative, 18% Her2 + and 12% luminal A; 52% of the patients had stage III of the disease; 75% (129) of the patients underwent a modified radical mastectomy. As a conclusion, the complete pathological response in patients with neoadjuvant treatment is related to molecular subtypes and this is statistically significant. Also, the highest rates of complete pathological response in the molecular groups of Her2 + and triple negative were evident.


Subject(s)
Humans , Female , Middle Aged , Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant , Anthracyclines/therapeutic use , Taxoids/therapeutic use , Breast Neoplasms/classification , Breast Neoplasms/pathology , Cross-Sectional Studies , Dose-Response Relationship, Drug , Drug Therapy, Combination
12.
J. health med. sci. (Print) ; 6(1): 29-36, ene.-mar. 2020. ilus
Article in Spanish | LILACS (Americas) | ID: biblio-1096530

ABSTRACT

En la actualidad, los análisis de distribución espacial mediante el uso de técnicas de clusters para enfermedades crónicas como el cáncer de mama, son relevantes para la identificación de patrones espaciales de la mortalidad por cáncer según áreas geográficas. Identificar clústeres espaciales de la mortalidad por cáncer de mama en mujeres a nivel de las provincias del Ecuador, entre 2004 al 2018. Estudio observacional, de tipo descriptivo, ecológico multigrupal que compara a nivel espacio ­ temporal las tasas de mortalidad por cáncer de mama en mujeres según las provincias del Ecuador, utilizando el índice de Móran para el análisis de autocorrelación y el algoritmo de k-medias para el análisis de agrupamiento en períodos quinquenales mediante el programa informático ArcGIS versión 10.5. Resultados. En el Ecuador, el 86,5% de las muertes por cáncer de mama en mujeres se registraron en el área urbana, dichas muertes tienen un patrón no aleatorio según el índice de Morán, distinto al área rural que tiene un patrón aleatorio; se identificó diferencia en el agrupamiento de la mortalidad por cáncer de mama en las provincias urbanas y rurales, donde se obtuvo para el área urbana, clústeres con altas, media-altas, media-baja y bajas tasas de mortalidad, mientras que en lo rural se obtuvieron solo clústeres con altas, medias y bajas tasas de mortalidad. La distribución espacial y el análisis de agrupamiento identificó clústeres de la mortalidad por cáncer de mama en el Ecuador, evidenciando entre lo urbano y rural diferencias en los clústeres obtenidos, siendo esta información de utilidad para la implementación de estrategias de control del cáncer en el país.


Currently spatial distribution analyzes through the use of cluster techniques for chronic diseases such as breast cancer are revealing for the identification of spatial patterns of cancer mortality according to geographic areas. Objective. Identify spatial clusters of breast cancer mortality in women at the level of the provinces of Ecuador, between 2004 to 2018. We used an observational, descriptive, ecological multigroup study that compares at a Spatio-temporal level the rates of breast cancer mortality in women according to the provinces of Ecuador, using the Moran index for the autocorrelation analysis and the k-, means algorithm for cluster analysis in five-year periods using the ArcGIS version 10.5 software. Results. In Ecuador, 86.5% of breast cancer deaths in women were recorded in the urban area, these deaths have a non-random pattern according to the Morán Index different from the rural area that has a random pattern; difference was identified in the grouping of breast cancer mortality in urban and rural provinces, where it was obtained for urban areas, clusters with high, medium. high, medium-low and low mortality rates. While in rural areas only clusters with high, medium and low mortality rates were obtained. Conclusions. The spatial distribution and cluster analysis identified clusters of breast cancer mortality in Ecuador; evidencing between urban and rural differences in the clusters obtained, this information is useful for the development of cancer control strategies in the country.


Subject(s)
Humans , Female , Breast Neoplasms/mortality , Cluster Analysis , Rural Areas , Demography , Urban Area , Ecuador/epidemiology , Spatial Analysis
13.
Acta méd. costarric ; 62(1): 18-25, ene.-mar. 2020. tab, graf
Article in Spanish | LILACS (Americas) | ID: biblio-1088533

ABSTRACT

Resumen Antecedente y objetivo: El cáncer es una de las enfermedades que genera mayor mortalidad en el mundo. Los programas de rehabilitación basados en ejercicios se muestran efectivos y seguros para mitigar los efectos del cáncer. El objetivo fue determinar los cambios de la fatiga asociada al cáncer de mama luego de un programa de entrenamiento de alta intensidad (HIIT), o continuo a intensidad moderada (MICT). Métodos: Ensayo clínico aleatorizado con 236 pacientes con cáncer de mama en estadio II, distribuidos en 3 grupos (MICT, HIIT y grupo control), a quienes se les aplicó la escala FACT Fatigue Scale, test de calidad de vida, ecocardiograma, prueba de esfuerzo, tolerancia y percepción nal ejercicio mediante la prueba de caminata de los 6 minutos y escala de Borg, respectivamente. El programa de entrenamiento tuvo una duración de 36 sesiones de 70 minutos, 3 veces por semana. Resultados: Luego de comparar los respectivos grupos, se evidenció cambios significativos en todas las variables de los grupos HIIT y MICT (p=<0,05 %) frente al grupo control. Además, hubo una mejoría posentrenamiento, de la fatiga asociada al cáncer de mama en el grupo HIIT (20,4±5,6 vs 5,1±3,6) y MICT (18.6±9.5 vs 8.0±4.2). Conclusiones: Estos tipos de entrenamiento mejoraron la tolerancia al ejercicio, fuerza, vo2 y sobre todo, la fatiga asociada al cáncer y la calidad de vida de las pacientes. Y el grupo control de atención habitual sin entrenamiento físico o ejercicio supervisado, no presentó cambios significativos ni mejoras en la fatiga asociada al cáncer de mama. Trial registration: Clinicaltrials.gov NCT03915288


Abstract Background and objective: Cancer is one of the diseases that generate the highest mortality in the world. Exercise-based rehabilitation programs are effective and safe to mitigate the effects of cancer. The objective was to determine the changes in fatigue associated with breast cancer after a highintensity training program (HIIT), or a continuous training at moderate intensity (MICT). Methods: Randomized clinical trial with 236 patients with stage II breast cancer, distributed in 3 groups (MICT, HIIT, and control group), to whom the FACT-Fatigue Scale and quality of life test were applied and an effort echocardiogram was performed. Tolerance, and perception of the exercise were evaluated through the test of walk of the 6 minutes and scale of Borg respectively. The training program lasted 36 sessions of 70 minutes, 3 times per week. Results: After comparing the respective groups, significant changes were evident in all the variables of the HIIT and MICT groups (p = <0.05%) compared to the control group. Also, there was a postworkout improvement of fatigue associated with breast cancer in the HIIT group (20.4 ± 5.6 vs. 5.1 ± 3.6) and MICT (18m6 ± 9m5 vs. 8m0 ± 4m2). Conclusions: These types of training improved exercise tolerance, strength, VO2 and, above all, cancer-associated fatigue and patients quality of life. The usual care control group without physical training or supervised exercise did not show significant changes or improvements in fatigue associated with breast cancer. Trial registration: Clinicaltrials.gov NCT03915288


Subject(s)
Humans , Breast Neoplasms , Exercise , Exercise Therapy , Fatigue/rehabilitation , High-Intensity Interval Training , Endurance Training
14.
Rev. bras. promoç. saúde (Impr.) ; 33: 1-10, 03/01/2020.
Article in English, Portuguese | LILACS (Americas) | ID: biblio-1099760

ABSTRACT

Objetivo: Descrever as estratégias de enfrentamento e de apoio às mulheres ocorridas após o diagnóstico de câncer de mama. Métodos: Trata-se de uma pesquisa descritiva e qualitativa, realizada de março a abril de 2019, na cidade de Pau dos Ferros, Rio Grande do Norte, Brasil, desenvolvida com sete mulheres vinculadas ao Núcleo de Apoio aos Portadores de Câncer. A coleta de dados foi realizada mediante entrevista semiestruturada, analisada através da análise de conteúdo, surgindo as categorias temáticas: Diagnóstico - Sentença de morte ou possiblidade de cura; Repercussões na vida cotidiana - principais mudanças e os seus aspectos diante do adoecimento; A importância das relações para o enfrentamento do câncer de mama - família, amigos e cônjuge; Núcleo de apoio aos portadores de câncer - Educação e promoção em saúde. Resultados: Diante do diagnóstico, as mulheres buscaram no cônjuge, na família, nos amigos e na religião/espiritualidade medidas de superação. Ocorreram mudanças de hábitos alimentares e a necessidade de afastamento do trabalho. Conclusão: O estudo permitiu conhecer as dificuldades ocorridas na vida de mulheres com o diagnóstico de câncer de mama, as quais são de ordem emocional, social e familiar. Evidenciou-se, ainda, que esta neoplasia promove mudanças no estilo de vida, negativas ou positivas.


Objective: To describe coping and supporting strategies for women after breast cancer diagnosis. Methods: This qualitative descriptive study was conducted from March to April 2019 in the city of Pau dos Ferros, Rio Grande do Norte, Brazil, with seven women served by the Cancer Patients Support Center. Data were collected using semi-structured interviews and submitted to content analysis, which yielded the following thematic categories: Diagnosis - Death sentence or possibility of cure; Repercussions in daily life - Main changes and their aspects in the face of illness; The importance of relationships in coping with breast cancer - family, friends and spouse; Cancer Patients Support Center ­ Health education and promotion. Results: Faced with the diagnosis, women looked out for overcoming measures in their spouses, families, friends and even religion/spirituality. They changed their eating habits and took a leave from work. Conclusion: This study allowed to understand the difficulties women face after breast cancer diagnosis. These difficulties include emotional, social and family problems. We also found that this type of neoplasm causes both positive and negative changes in their lifestyle.


Objetivo: Describir las estrategias de afrontamiento y de apoyo a las mujeres tras el diagnóstico de cáncer de mama. Métodos: Se trata de una investigación descriptiva y cualitativa realizada entre marzo y abril de 2019 en la ciudad de Pau dos Ferros, Rio Grande do Norte, Brasil, desarrollada con siete mujeres del Núcleo de Apoyo a los Portadores de Cáncer. La recogida de datos se dio a través de entrevista semiestructurada que ha sido analizada por el análisis de contenido de la cual se ha presentado las categorías temáticas a continuación: Diagnóstico ­ Sentencia de muerte o posibilidad de cura; Repercusiones de la vida cotidiana ­ principales cambios y sus aspectos ante la enfermedad; La importancia de las relaciones para el afrontamiento del cáncer de mama ­ la familia, los amigos y el cónyuge; Núcleo de apoyo a los portadores de cáncer ­ Educación y promoción de la salud. Resultados: Ante el diagnóstico las mujeres buscaron los cónyuges, la familia, los amigos y la religión/espiritualidad como medidas de superación. Ocurrieron cambios de hábitos alimentarios y la necesidad de alejamiento del trabajo. Conclusión: El estudio ha permitido el conocimiento de las dificultades emocionales, sociales y familiares de la vida de mujeres con el diagnóstico de cáncer de mama. Se ha evidenciado, aún, que esta neoplasia genera cambios negativos o positivos en el estilo de vida.


Subject(s)
Breast Neoplasms , Emotional Adjustment , Health Promotion
15.
Article in English | WPRIM (Western Pacific) | ID: wprim-762478

ABSTRACT

No abstract available.


Subject(s)
Breast Neoplasms , Breast , Genetic Testing
16.
Article in English | WPRIM (Western Pacific) | ID: wprim-762476

ABSTRACT

Hereditary breast cancer is known for its strong tendency of inheritance. Most hereditary breast cancers are related to BRCA1/BRCA2 pathogenic variants. The lifelong risk of breast cancer in pathogenic BRCA1 and BRCA2 variant carriers is approximately 65% and 45%, respectively, whereas that of ovarian cancer is estimated to be 39% and 11%, respectively. Therefore, understanding these variants and clinical knowledge on their occurrence in breast cancers and carriers are important. BRCA1 pathogenic variant breast cancer shows more aggressive clinicopathological features than the BRCA2 pathogenic variant breast cancer. Compared with sporadic breast cancer, their prognosis is still debated. Treatments of BRCA1/BRCA2 pathogenic variant breast cancer are similar to those for BRCA-negative breast cancer, mainly including surgery, radiotherapy, and chemotherapy. Recently, various clinical trials have investigated poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor treatment for advanced-stage BRCA1/BRCA2 pathogenic variant breast cancer. Among the various PARP inhibitors, olaparib and talazoparib, which reached phase III clinical trials, showed improvement of median progression-free survival around three months. Preventive and surveillance strategies for BRCA pathogenic variant breast cancer to reduce cancer recurrence and improve treatment outcomes have recently received increasing attention. In this review, we provide an information on the clinical features of BRCA1/BRCA2 pathogenic variant breast cancer and clinical recommendations for BRCA pathogenic variant carriers, with a focus on treatment and prevention strategies. With this knowledge, clinicians could manage the BRCA1/BRCA2 pathogenic variant breast cancer patients more effectively.


Subject(s)
Breast Neoplasms , Breast , Disease-Free Survival , Drug Therapy , Humans , Ovarian Neoplasms , Poly(ADP-ribose) Polymerase Inhibitors , Prognosis , Radiotherapy , Recurrence , Wills
17.
Article in English | WPRIM (Western Pacific) | ID: wprim-785393

ABSTRACT

Methods for reproducibly isolating and enriching small extracellular vesicles (EVs) from blood are essential for clinical utilization of small EVs in cancer patients. We combined ultracentrifugation (UC) with polymer-based precipitation (ExoQuick [EQ] or Total Exosome Isolation [TEI] kit) to isolate small EVs (diameter, 30–150 nm) from the serum of breast cancer patients. We compared the performance of four cycles of UC (UC4x) with that of two cycles of UC followed by enrichment using the EQ (UC2x→EQ) or TEI (UC2x→TEI) kits. The mean concentration of small EVs isolated from 1 mL of serum using UC2x→EQ (139.0±29.1 µg) and UC2x→TEI (140.4±5.0 µg) did not differ from that obtained using UC4x (141.8±26.9 µg). The mean number of EV particles obtained using UC4x was 29.2±9.9×109 per mL of serum, whereas UC2x→EQ and UC2x→TEI yielded higher numbers of EVs (50.7±17.0×10⁹ and 59.3±20.6×10⁹, respectively). Concentrations of EV microRNAs, including miR-21 and miR-155, did not differ between the three methods. In conclusion, performing UC prior to the use of polymer-based precipitation kits could be feasible for isolating small EVs from human serum in large sample-based translational researches.


Subject(s)
Breast Neoplasms , Extracellular Vesicles , Humans , MicroRNAs , Translational Medical Research , Ultracentrifugation
18.
Article in English | WPRIM (Western Pacific) | ID: wprim-812980

ABSTRACT

Lung adenocarcinoma is a malignant tumor that is prone to distant metastasis. Common metastatic sites are brain, adrenal gland, liver, bone, and so on. Skin soft tissue metastasis is unusual, and breast metastasis is even rarer. This case is a middle-aged female patient who had experienced multi-line treatments for upper limbs, abdominal skin, and bilateral breast tissue metastases.The patient's multiple metastases were susceptible to radiation therapy.Reviewing the entire treatment process of this patient can find that the rational use of individualized comprehensive treatment methods and appropriate timing of genetic testing are very important for patients with lung adenocarcinoma to prolong their survival time and improve their quality of life.


Subject(s)
Adenocarcinoma of Lung , Breast Neoplasms , Female , Humans , Lung Neoplasms , Middle Aged , Quality of Life
19.
Article in Korean | WPRIM (Western Pacific) | ID: wprim-811250

ABSTRACT

PURPOSE: This study evaluated the effects of nutrition management application in a mobile device on obesity management of patients with breast cancer.METHODS: Fifty subjects, who were breast cancer survivors, aged 30 years and older, participated in an obesity management program for four weeks. They were divided randomly into two groups: a control group (n = 25) and a treatment group (n = 25). The treatment group was provided an application for nutrition management and diet consultant, while the control group maintained their ordinary life without any nutrition management.RESULTS: The weight of the treatment group decreased by 0.8 kg, but the change was not significant. In contrast, the waist-hip ratio of the treatment group decreased significantly from 0.75 to 0.71 (p = 0.012). The Nutrition Quotients of the treatment group increased significantly from 61.3 to 69.6 points (p < 0.001), whereas that of the control group decreased significantly from 61.5 to 59.0 (p = 0.002).CONCLUSION: This mobile nutrition management application for breast cancer patients is effective in managing obesity and dietary habits. These results can be used as basic information to prepare an obesity management program for breast cancer patients.


Subject(s)
Breast Neoplasms , Breast , Consultants , Diet , Diet Therapy , Feeding Behavior , Humans , Mobile Applications , Obesity , Survivors , Waist-Hip Ratio
20.
Article in English | WPRIM (Western Pacific) | ID: wprim-811201

ABSTRACT

Matrix metallopeptidase 3 or MMP3, is a zinc-dependent proteolytic enzyme that is involved in various physiological processes via modification of the extracellular matrix. In particular, its over-expression has been associated with cancer metastasis and tumor growth in various cancers including breast cancer. MMP3 gene expression is regulated by several factors such as DNA polymorphisms which also serve as risk factors for breast cancer. As such, DNA polymorphisms of MMP3 have the potential to be utilized as genetic biomarkers for prediction and prognosis of metastatic breast cancer. Presently, genome-wide association studies of MMP3 gene polymorphisms which are associated with breast cancer risk and patient survival in a variety of populations are reviewed. In order to understand the potential role of MMP3 polymorphisms as genetic markers for breast cancer metastasis, the domain structure of MMP3, the regulation of its expression and its role in breast cancer metastasis are also briefly discussed in this review. The emergence of MMP3 gene polymorphisms as prognostic biomarker candidates for breast cancer metastasis may contribute towards improving targeted therapies and categorization of breast cancer cases in order to provide a better and more accurate prognosis.


Subject(s)
Biomarkers , Breast Neoplasms , Breast , DNA , Extracellular Matrix , Gene Expression , Genetic Markers , Genome-Wide Association Study , Humans , Matrix Metalloproteinase 3 , Neoplasm Metastasis , Physiological Phenomena , Prognosis , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL